Gamma Knife Radiosurgery - Revision history

Lazy at 08:25, 18 January 2025

2025-01-18T08:25:36Z

← Older revision		Revision as of 01:25, 18 January 2025
Line 16:		Line 16:
	\|book_text=Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols.		\|book_text=Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols.
	\|links=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10162-w		\|links=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10162-w
	}}		\|overview=Gamma Knife Radiosurgery (GKRS) offers a promising and safer alternative for treating newly diagnosed Glioblastoma Multiforme (GBM), characterized by lower toxicity and comparable overall and progression-free survival rates compared to standard treatments. This established modality, particularly when using fractionated sessions with the Gamma Knife ICON, emphasizes patient safety while highlighting the need for further research to optimize treatment protocols.}}

Lazy at 02:54, 18 November 2024

2024-11-18T02:54:59Z

← Older revision		Revision as of 19:54, 17 November 2024
Line 10:		Line 10:
	\|PFS_with=5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.		\|PFS_with=5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.
	\|usefulness_rating=3		\|usefulness_rating=3
			\|treatment_category=Radiation
	\|usefulness_explanation=The primary advantage of GKRS for GBM lies in its lower toxicity profile, offering a safer treatment option for select patients without compromising on the progression-free survival (PFS) or overall survival (OS) rates.		\|usefulness_explanation=The primary advantage of GKRS for GBM lies in its lower toxicity profile, offering a safer treatment option for select patients without compromising on the progression-free survival (PFS) or overall survival (OS) rates.
	\|toxicity_level=2		\|toxicity_level=2

Lazy at 05:52, 30 March 2024

2024-03-30T05:52:03Z

← Older revision		Revision as of 22:52, 29 March 2024
Line 14:		Line 14:
	\|toxicity_explanation=GKRS, especially when utilized in a fractionated approach with the Gamma Knife ICON, presents a viable treatment option for GBM patients, emphasizing reduced side effects while maintaining efficacy.		\|toxicity_explanation=GKRS, especially when utilized in a fractionated approach with the Gamma Knife ICON, presents a viable treatment option for GBM patients, emphasizing reduced side effects while maintaining efficacy.
	\|book_text=Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols.		\|book_text=Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols.
			\|links=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10162-w
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Gamma Knife Radiosurgery (GKRS) for GBM |FDA_approval=Yes |used_for=Newly diagnosed Glioblastoma Multiforme (GBM) |clinical_trial_phase=N/A (Established treatment modality) |common_side_effects=Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies. |OS_without=14-16 months with standard treatment. |OS_with=Comparable to standard treatment, specifics depend on individual patient..."

2024-03-30T05:51:00Z

Created page with "{{TreatmentInfo |drug_name=Gamma Knife Radiosurgery (GKRS) for GBM |FDA_approval=Yes |used_for=Newly diagnosed Glioblastoma Multiforme (GBM) |clinical_trial_phase=N/A (Established treatment modality) |common_side_effects=Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies. |OS_without=14-16 months with standard treatment. |OS_with=Comparable to standard treatment, specifics depend on individual patient..."

New page

{{TreatmentInfo
|drug_name=Gamma Knife Radiosurgery (GKRS) for GBM
|FDA_approval=Yes
|used_for=Newly diagnosed Glioblastoma Multiforme (GBM)
|clinical_trial_phase=N/A (Established treatment modality)
|common_side_effects=Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies.
|OS_without=14-16 months with standard treatment.
|OS_with=Comparable to standard treatment, specifics depend on individual patient factors.
|PFS_without=Typically, tumors recur within 6 months of standard treatment.
|PFS_with=5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.
|usefulness_rating=3
|usefulness_explanation=The primary advantage of GKRS for GBM lies in its lower toxicity profile, offering a safer treatment option for select patients without compromising on the progression-free survival (PFS) or overall survival (OS) rates.
|toxicity_level=2
|toxicity_explanation=GKRS, especially when utilized in a fractionated approach with the Gamma Knife ICON, presents a viable treatment option for GBM patients, emphasizing reduced side effects while maintaining efficacy.
|book_text=Gamma Knife Radiosurgery (GKRS) provides a novel approach for the management of newly diagnosed glioblastoma (GBM), emphasizing lower toxicity without significant alteration in progression-free or overall survival rates. This treatment modality, particularly with the advent of fractionated sessions using the Gamma Knife ICON, indicates a strategic shift towards maximizing patient safety and treatment tolerability. Further investigation in a prospective setting is warranted to fully ascertain the benefits and optimize treatment protocols.
}}